These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 12110994)

  • 1. Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
    Cussac D; Duqueyroix D; Newman-Tancredi A; Millan MJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):168-77. PubMed ID: 12110994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
    Newman-Tancredi A; Rivet JM; Cussac D; Touzard M; Chaput C; Marini L; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):188-99. PubMed ID: 12923612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
    Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
    Newman-Tancredi A; Verrièle L; Touzard M; Millan MJ
    Eur J Pharmacol; 2001 Oct; 428(2):177-84. PubMed ID: 11675034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.
    Newman-Tancredi A; Verrièle L; Millan MJ
    Br J Pharmacol; 2001 Jan; 132(2):518-24. PubMed ID: 11159702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors.
    Audinot V; Newman-Tancredi A; Cussac D; Millan MJ
    Neuropsychopharmacology; 2001 Sep; 25(3):410-22. PubMed ID: 11522469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
    Dekeyne A; Rivet JM; Gobert A; Millan MJ
    Neuropharmacology; 2001 Jun; 40(7):899-910. PubMed ID: 11378160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells.
    Cosi C; Koek W
    Eur J Pharmacol; 2001 Dec; 433(1):55-62. PubMed ID: 11755134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s.
    Dupuis DS; Mannoury la Cour C; Chaput C; Verrièle L; Lavielle G; Millan MJ
    Eur J Pharmacol; 2008 Jul; 588(2-3):170-7. PubMed ID: 18511034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.
    Bruins Slot LA; Palmier C; Tardif S; Cussac D
    Neuropharmacology; 2007 Aug; 53(2):232-41. PubMed ID: 17588617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
    Newman-Tancredi A; Gavaudan S; Conte C; Chaput C; Touzard M; Verrièle L; Audinot V; Millan MJ
    Eur J Pharmacol; 1998 Aug; 355(2-3):245-56. PubMed ID: 9760039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system.
    Khawaja XZ; Smith DL; Nawoschik SP; Zhang J; Dunlop J; Dilks DW; Olsen M; Schechter LE
    J Neurochem; 2006 Jul; 98(1):134-45. PubMed ID: 16805803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol.
    Cussac D; Newman-Tancredi A; Nicolas JP; Boutin JA; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):549-54. PubMed ID: 10832610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
    Herrick-Davis K; Grinde E; Teitler M
    J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
    Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
    Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.